October 20, 2016
CosmosID Partners with Cancer Moonshoot Initiative
CosmosID announced participation in Vice President Biden’s National Cancer Moonshot, which aims to accelerate progress in preventing, diagnosing, and treating cancer. CosmosID will provide access to its automated bioinformatics platform, MetaGenID, for five cancer microbiome research studies (valued at $150,000) to understand how the microbiome (i.e. oral, gut, and skin) contributes to development of specific cancers.
This new effort will focus on those human cancers in which changes in the microbial community and/or association of specific microbes have been linked to gastric, lung, oral, pancreatic, or cervical cancers. For these five cancer studies, data collected in the analyses will be made freely available to researchers to answer critical questions concerning the microbiome and its role in development, management, and treatment of human cancers.
CosmosID MetaGenID contains over 65,000 highly curated microbial genomes and is capable of ultra-rapid high resolution strain level identification of microorganisms, including bacteria, viruses, fungi, and parasites, and also provides antibiotic resistance and virulence marker profiling.
In its contribution to the Cancer Moonshot initiative, CosmosID launched a web portal to facilitate applications by scientists and researchers for access to the MetaGenID bioinformatics tool for cancer microbiome studies. “There are many pieces of the cancer puzzle to figure out and we are very pleased to offer our support by providing high resolution microbiome characterization to help in both early detection and therapeutic development” said Manoj Dadlani, CosmosID’s CEO.